Accelerator Reaches Out to East Coast to Find Latest Startup, Acylin Therapeutics

Seattle-based Accelerator has invested in Boston based Acylin Therapeutics. The biotech startup will focus their small molecule drug discovery efforts on histone acetyltransferases (HATs), enzymes that work in concert with histone deactylases (HDACs) to regulate chromosome structure and transcriptional activity. While several companies are developing HDAC based drugs for the treatment of neurodegenerative diseases, Acylin is the first to focus attention on the complementary HAT class of enzymes.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail